[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
November 19, 2014

Fixed-Dose Combination Therapy (Polypill) for the Prevention of Cardiovascular Disease

Author Affiliations
  • 1Department of Preventive Medicine, Northwestern University, Chicago, Illinois
  • 2Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom
  • 3Department of Noncommunicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Camden, United Kingdom
JAMA. 2014;312(19):2030-2031. doi:10.1001/jama.2014.13616
Abstract

Clinical Question  Is fixed-dose combination therapy (polypill) that combines antiplatelet, blood pressure–lowering, and cholesterol-lowering medications into a single pill associated with improved cardiovascular disease (CVD) risk factors or reduced all-cause mortality or fatal and nonfatal CVD events? Is the polypill associated with an increase in adverse events?

Bottom Line  Polypills are associated with greater reductions in systolic blood pressure and total cholesterol compared with usual care, placebo, or active comparators, but also with a 19% higher risk of any adverse event. Due to limited power from available evidence, the association of polypills with all-cause mortality or fatal and nonfatal CVD events is uncertain.

×